FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries
The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...
Gene therapy
Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...
Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion
US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...
Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients
Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for...
YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101
Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...
StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...
Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss
South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy
China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...
Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...
AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...
Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...